1[1]Paez JG,J(a)nne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304(5676):1497-1500.
2[2]Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med,2004,350(21):2129-2139.
3[3]Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci U S A,2004,101(36):13306-13311.
4[4]Chan SK,Gullick WJ,Hill ME.Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy.Eur J Cancer,2006,42 (1):17-23.
5[5]Mu XL,Li LY,Zhang XT,et al.Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.Clin Cancer Res,2005,11(12):4289-4294.
10[10]Kosaka T,Yatabe Y,Endoh H,et al.Mutations of the epidermal growth factor receptor gene in lung cancer:biological and clinical implications.Cancer Res,2004,64(24):8919-8923.
3Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med, 2002,346(2):92-98.
4Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities [J]. Eur J Cancer, 2001,37(Suppl 4) :S3-8.
5Schlesinger J. Cell signaling by receptor tyrosine kinases [J].Cell, 2000,103(2) :211-225.
6Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy [J]. Pharmacol Ther, 1999,82(2-3) :241-250.
7Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer [J]. Eur J Cancer,1996,32A (12): 2070-2074.
8Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [J]. J Clin Oncol, 2003,21(12):2237-2246.
9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial [J]. JAMA, 2003,290(16) :2149-2158.
10Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC [J]. J Clin Oncol, 2003,21 (14): 2658-2663.
